Taken together, this study proposes miR-18a as a promising therapeutic target in cisplatin-resistant ovarian cancer and validates MMP-3 as a direct miR-18a target in cisplatin-resistant ovarian cancer cells. Here, MMP3 is linked to ovarian carcinoma.